ConductScience.org, home
OVCAR-3
API referenceFor AI assistants

Cell line · CVCL_0465

Papers234

3 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.

1 to 20 of 234

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation.Oncol Res2026Its Methods give the RRID and name the linePubMed
Exosomal circ_0000387 Is Associated With Ovarian Cancer Metastatic Regulation Through IGF2BP3-Related Signalling and Endothelial VWF Responses.J Biochem Mol Toxicol2026Its Methods give the RRID and name the linePubMed
Boosting ovarian cancer immunotherapy via discoidin domain receptor 2 blockade and CD28 x mucin 1 bispecific antibodies.BMC Med2026Its Methods give the RRID and name the linePubMed
Distinct and Convergent Roles of the Synovial Sarcoma X Breakpoint Family of Cancer-Testis Antigens in Ovarian Cancer.Int J Mol Sci2026Its Methods give the RRID and name the linePubMed
Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer.Mol Oncol2026Its Methods give the RRID and name the linePubMed
A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.Transl Oncol2026Its Methods give the RRID and name the linePubMed
A guide to selecting high-performing antibodies for Netrin-1 (UniProt ID: O95631) for use in western blot and immunoprecipitation.F1000Res2026Its Methods give the RRID and name the linePubMed
Scalable generation of hematopoietic stem cell-engineered off-the-shelf mono-specific cytotoxic T cells targeting solid tumors.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells.Cancer Immunol Res2026Its Methods give the RRID and name the linePubMed
Optimization of hinge domain enhances antitumor efficacy of globo H-targeted CAR-T cells in solid tumor models.iScience2026Its Methods give the RRID and name the linePubMed
Targeting CD24 Activates Macrophages to Reduce Tumor Burden in Preclinical Models of Solid Tumors.Clin Cancer Res2026Its Methods give the RRID and name the linePubMed
Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression.iScience2026Its Methods give the RRID and name the linePubMed
Anti-PD1-IL18 immunoconjugate promotes effector T cell-mediated antitumor immunity.J Immunother Cancer2026Its Methods give the RRID and name the linePubMed
Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters.Cell Rep Methods2026Its Methods give the RRID and name the linePubMed
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.Cancer Res2026Its Methods give the RRID and name the linePubMed
Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.Mol Oncol2026Its Methods give the RRID and name the linePubMed
DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.iScience2026Its Methods give the RRID and name the linePubMed
KPNA2 Drives Immunosuppression in Ovarian Cancer via CCL2/CCR2-Dependent MDSC Recruitment.Cancer Sci2026Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_0465/papers

API referenceFor AI assistants